Hostname: page-component-8448b6f56d-jr42d Total loading time: 0 Render date: 2024-04-20T01:09:16.045Z Has data issue: false hasContentIssue false
  • English
  • Français

Non-Invasive Testing, Non-Invasive Counseling

Published online by Cambridge University Press:  01 January 2021

Rachel Rebouché
Get access Rights & Permissions [Opens in a new window]

Extract

A regulatory moment for prenatal health care is here. An increasing amount of legislative attention has concentrated on the decisions pregnant women make after prenatal testing. The impetus for this legislation is a new non-invasive prenatal genetic test (NIPT). From the beginning of pregnancy, cell-free fetal DNA travels across the placental lining into the mother’s bloodstream, increasing in quantity as the pregnancy progresses. Laboratories can now analyze that DNA for chromosomal abnormalities and for fetal sex at 10 weeks of gestation. NIPT, which relies on a sample of the pregnant woman’s blood, is painless, occurs early in pregnancy, and is available for clinical and commercial use. In 2013, major health insurance plans began to cover NIPT for certain populations of women, such as women over 35 years old. And private companies have started marketing prenatal testing kits directly to consumers, who return a blood sample from the prospective mother to a company laboratory.

Type
Symposium
Information
Journal of Law, Medicine & Ethics , Volume 43 , Issue 2 , Summer 2015 , pp. 228 - 240
Copyright
Copyright © American Society of Law, Medicine and Ethics 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Agarwal, A. et al., “Commercial Landscape of Noninvasive Prenatal Testing in the United States,” Prenatal Diagnosis 33, no. 6 (2013): 521–531, at 521.Google Scholar
Id.; Zettler, P. et al., “23andMe, the Food and Drug Administration, and the Future of Genetic Testing,” JAMA Internal Medicine, February 17, 2014, available at <http://archinte.jamanetwork.com/article.aspx?articleid=1830023> (last visited April 17, 2015).+(last+visited+April+17,+2015).>Google Scholar
Rao, R., “Equal Liberty: Assisted Reproductive Technology and Reproductive Equality,” George Washington Law Review 76, no. 6 (2008): 1457–1489, at 1457.Google Scholar
Va. Code Ann. § 54.1–2957.20 (2014).CrossRefGoogle Scholar
See, e.g., Hill, M. et al., “Non-Invasive Prenatal Determination of Fetal Sex: Translating Research into Clinical Practice,” Clinical Genetics 80, no. 1 (2011): 68–75, at 70.CrossRefGoogle Scholar
See, e.g., Sayres, L. C. et al., “Cell-Free Fetal DNA Testing: A Pilot Study of Obstetric Healthcare Provider Attitudes toward Clinical Implementation,” Prenatal Diagnosis 31, no. 11 (2011): 1070–1076, at 1071.CrossRefGoogle Scholar
Klitzman, R., Am I My Genes?: Confronting Fate and Family Secrets in the Age of Genetic Testing (Oxford: Oxford University Press, 2012): At 230.Google Scholar
Robertson, J. A., “Genetic Selection of Offspring Characteristics,” Boston University Law Review 76, no. 3 (1996): 421–482, at 427; King, J. S., “Not This Child: Constitutional Questions in Regulating Noninvasive Prenatal Genetic Diagnosis and Selective Abortion,” University of California Los Angeles Law Review 60, no. 1 (2012): 2–75, at 61.Google Scholar
Rebouché, R., “Testing Sex,” University of Richmond Law Review 49, no. 1 (2015): 519–577, at 562–569 (focusing on why sex selective bans may survive constitutional challenge).Google Scholar
Swanson, A. et al., “Non-invasive Prenatal Testing: Technologies, Clinical Assays and Implementation Strategies for Women's Healthcare Practitioners,” Current Genetic Medicine Reports 1, no. 2 (2013): 113–121, at 114.Google Scholar
Wright, C. F. Burton, H., “The Use of Cell-free Fetal Nucleic Acids in Maternal Blood for Non-invasive Prenatal Diagnosis,” Human Reproduction Update 15, no. 1 (2009): 139–151, at 139–140.CrossRefGoogle Scholar
Id., at 139.Google Scholar
Id., at 142–143. There are different sequencing technologies laboratories can use: Massively parallel sequencing, targeted sequencing of specific chromosomal segments, or directed sequence analysis of single nucleotide polymorphisms.Google Scholar
Powell, C. M., “The Current State of Prenatal Testing in the United States,” in Parens, E. Asch, A., eds., Prenatal Testing and Disability Rights (Washington, D.C.: Georgetown University Press, 2000): At 45.Google Scholar
Mujezinovic, F. Alfirevic, Z., “Procedure-Related Complications of Amniocentesis and Chorionic Villous Sampling: A Systematic Review,” Obstetrics & Gynecology 110, no. 3 (2007): 687–694, at 687.Google Scholar
Driscoll, D. A. Gross, S. J., “ACOG Practice Guidelines: Screening for Fetal Aneuploidy & Neural Tube Defects,” Genetics in Medicine 11, no. 11 (2009): 818–821, at 818.CrossRefGoogle Scholar
Suter, S., “The Routinization of Prenatal Testing,” American Journal of Law & Medicine 28, no. . 2 & 3 (2002): 233–270, at 234.CrossRefGoogle Scholar
Odeh, M. et al., “Sonographic Fetal Sex Determination,” Obstetrics & Gynecology Survey 64, no. 1 (2009): 50–57, at 50.Google Scholar
See Driscoll, Gross, , supra note 16, at 818–821; American Congress of Obstetricians & Gynecologists, “ACOG Practice Bulletin No. 77: Screening for Fetal Chromosomal Abnormalities,” Obstetrics & Gynecology 109, no. 1 (2007): 217–220.Google Scholar
Devaney, S. A. et al., “Noninvasive Fetal Sex Determination Using Cell-Free Fetal DNA,” JAMA 306, no. 6 (2011): 627–636, at 634; Palomaki, G. E. et al., “DNA Sequencing of Maternal Plasma Reliably Identifies Trisomy 18 and Trisomy 13 as Well as Down Syndrome: An International Collaborative Study,” Genetics in Medicine 14, no. 3 (2012): 296–305, at 296.CrossRefGoogle Scholar
See Powell 14, supra note, at 48.Google Scholar
See Devaney, et al., supra note, at 631–633. But see de Jong, A. Maya, I. van Litht, J., “Prenatal: Screening: Current Practice, New Developments, Ethical Challenges,” Bioethics 29, no. 1 (2015): 1–8, at 6 (noting that there is also a consistent reporting of false positives in NIPT studies).Google Scholar
Farrell, R. M. et al., “Risk & Uncertainty: Shifting Decision Making for Aneuploidy Screening to the First Trimester of Pregnancy,” Genetics in Medicine 13, no. 5 (2011): 429–436, at 434.CrossRefGoogle Scholar
de Jong, A. et al., “Non-invasive Prenatal Testing: Ethical Issues Explored,” European Journal Human Genetics 18, no. 3 (2010): 272–277, at 273.Google Scholar
Id., at 273.Google Scholar
King, J. S., “Politics and Fetal Diagnostics Collide,” Nature 491, no. 7422 (2012): 33–34, at 34.CrossRefGoogle Scholar
See, e.g., Illumina, Non-Invasive Prenatal Screening, “The Verifi Prenatal Test: The Proven Choice for NIPT,” available at <http://www.illumina.com/clinical/reproductive-genetic-health/patients/non-invasive-prenatal-screening.html/> (last visited May 6, 2015).+(last+visited+May+6,+2015).>Google Scholar
See Norton, et al., infra note 31, at 849 (noting also that the age “cut off” for pregnancy has been discredited by many); see also S. Morain, Greene, M. F. Mello, M. M., “A New Era in Noninvasive Prenatal Testing,” New England Journal of Medicine 369, no. 6 (2013): 499–501, at 501.Google Scholar
American College of Obstetricians and Gynecologists Committee on Genetics, Committee Opinion Number 545: Noninvasive Prenatal Testing for Fetal Aneuploidy (December 2012).Google Scholar
Bianchi, D. W., “At-Home Fetal DNA Gender Testing: Caveat Emptor,” Obstetrics & Gynecology 107, no. 2 (2006): 216–218, at 216.Google Scholar
Norton, M. E. Rose, N. C. Benn, P., “Noninvasive Prenatal Testing for Fetal Aneuploidy: Clinical Assessment and a Plea for Restraint,” Obstetrics & Gynecology 121, no. 4 (2013): 847–850, at 847–848 (stating that studies on NIPT rely on “archived samples with known karyotypes that intentionally included a large proportion of specimens from women with known aneuploidy fetuses”).Google Scholar
UnitedHealthcare, Medical Policy: Noninvasive Prenatal Diagnosis of Fetal Aneuploidy Using Cell-free Fetal Nucleic Acids in Maternal Blood, April 1, 2014, 1–13, at 3.Google Scholar
To date, companies have been somewhat cautious in direct-to-consumer advertising, but have developed sex determination tests consumers can buy online. Gail Javitt reports: “State laws vary with respect to whether [genetic] tests can be offered directly to consumers, and many states allow it. Moreover, even those tests that are currently physician mediated for the most part lack formal assurance from any of the traditional regulators that they provide information useful to health-care decision making.” Javitt, G. H., “Pink or Blue? The Need for Regulation Is Black and White,” Fertility & Sterility 86, no. 1 (2006): 13–15, at 14.CrossRefGoogle Scholar
See, e.g., UnitedHealthcare, supra note, at 3; Weaver, C., “Tough Calls on Prenatal Tests,” Wall Street Journal, April 3, 2013, available at <online.wsj.com/news/articles/SB10001424127887324883604578398791568615644> (last visited April 18, 2015).+(last+visited+April+18,+2015).>Google Scholar
Washington State Health Care Authority, Washington Apple Health, Prenatal Genetic Testing Provider Guide, July 1, 2014, at 6 (covering an initial counseling session that does not exceed ninety-minute session and then two follow-up sessions not exceeding ninety minutes).Google Scholar
Priority Health, Genetics: Counseling, Testing, Screening, Medical Policy No. 91540-R9, (October 19, 2013): 1–26, at 3.Google Scholar
See Swanson, et al., supra note 10, at 117.Google Scholar
See Agarwal, et al., supra note 1, at 522.Google Scholar
See Morain, et al., supra note 28, 499.Google Scholar
Daar, J. F., “ART and the Search for Perfectionism: On Selecting Gender, Genes, and Gametes,” Journal of Gender Race & Justice 9, no. 3 (2005): 241–272, at n.2.Google Scholar
Id., at 253, 261–262 (describing the “geneticization of assisted conception,” arguing that choices that PGD provides parents are similar to choices after amniocentesis or CVS and noting comparisons between abortion law and ART in assessing the status of the embryo).Google Scholar
Puri, S. Nachtigall, R. D., “The Ethics of Sex Selection: A Comparison of the Attitudes and Experiences of Primary Care Physicians and Physician Providers of Clinical Sex Selection Services,” Fertility & Sterility 93, no. 7 (2010): 2107–2114, at 2110.CrossRefGoogle Scholar
Perhaps the most significant difference is cost and thus access to PGD. PGD is an additional step in IVF and those two processes together can cost between $12,500 to $16,000, often paid out of pocket because IVF, and to a lesser extent PGD, is frequently not covered by health insurance. See Daar, , supra note 40, at n.48.Google Scholar
Mutcherson, K., “Making Mommies: Law, Pre-implantation Genetic Diagnosis, and the Complications of Pre-Motherhood,” Columbia Journal of Gender & Law 18, no. 1 (2008): 313–390, at 331.Google Scholar
For example, PRENDA states that sex selection “trivializes human reproduction by making it depend on the selection of non-essential features of offspring.” Prenatal Nondiscrimination Act of 2011, H.R. 447, 113th Cong. § 2(a)(1)(K) (2013).Google Scholar
de Jong, A. de Wert, G., “Prenatal Screening: An Ethical Agenda for the Near Future,” Bioethics 29, no. 1 (2015): 46–55, at 47.Google Scholar
Suter, S., “A Brave New World of Designer Babies?” Berkeley Technology Law Journal 22, no. 2 (2007): 897–969, at 944. See also de Jong, de Wert, , supra note 46, at 49.Google Scholar
Friedman, J. M., “Legal Implications of Amniocentesis,” University of Pennsylvania Law Review 123, no. 1 (1974): 92–156, at 107.Google Scholar
Guttmacher Institute, “Monthly State Updates: Major Developments in 2015,” available at <http://www.guttmacher.org/statecenter/updates/> (last visited May, 5 2015).+(last+visited+May,+5+2015).>Google Scholar
Id.Google Scholar
Rebouché, R. Rothenberg, K., “Mixed Messages: The Intersection of Prenatal Genetic Testing and Abortion,” Howard Law Journal 53, no. 3 (2012): 983–1023, at 992–998; see also Javitt, , supra note, at 14 (“For more than ten years, federal government officials have been discussing the need for improved oversight of genetic testing. Ten years and two Secretary-level advisory committees later, not a single piece of legislation— and little regulation—has been promulgated.”).Google Scholar
Id. (Rebouché and Rothenberg), at 987.Google Scholar
See Javitt, , supra note, at 14; see also King, , supra note 26, at 34 (“The FDA still has not developed a comprehensive regulatory scheme for genetic tests, despite repeated calls to do so from government advisory groups (such as the U.S. Secretary's Advisory Committee on Genetics, Health and Society) and nonprofit organizations (such as the Genetics and Public Policy Center).”).Google Scholar
Weiss, R. L., “The Long and Winding Regulatory Road for Laboratory Tests,” American Journal of Clinical Pathology 138, no. 1 (2012): 20–26, at 20.CrossRefGoogle Scholar
Id. The FDA signaled closer monitoring of adult, direct-to-consumer testing in 2013 when it issued a warning letter to the company 23andMe. 23andMe previously sold testing kits for health-related genetic reports, but had come under increasing scrutiny for the inaccuracy and the indeterminate nature of the reports sent to consumers. See Zettler, et al., supra note 2, at E1.Google Scholar
Benn, P. A. Chapman, A. R., “Ethical Challenges in Providing Non-invasive Prenatal Diagnosis,” Current Opinion in Obstetrics & Gynecology 22, no. 2 (2010): 128–134, at 129.Google Scholar
See Norton, et al., supra note 31, at 848.Google Scholar
57 Federal Register 7137 (1992) (codified at 42 C.F.R. § 493.1); Federal Food, Drug, Cosmetic Act, 21 U.S.C. §§ 321(h), 201(h) (standards for medical devices as opposed to laboratory-developed tests).Google Scholar
See Morain, et al., supra note 28, at 500. The Center for Disease Control recommends the ACCE model for vetting prenatal genetic tests – analytic validity, clinical validity, clinical utility, and ELSI (or the ethical, legal, social implications). See, e.g., UnitedHealthcare, supra note, at 3.Google Scholar
Id., at 847–848.Google Scholar
Id., at 848.Google Scholar
Mo. Rev. Stat. § 191.320 (2011).Google Scholar
Okla. Stat. tit. 63, § 1–568 (2006).Google Scholar
Tenn. Code Ann. § 68-5-504(a)(1) (2010) (“procedures or services designed to search out disorders in unborn children that are not treatable shall not be provided for under this part”).Google Scholar
Okla. Stat. Ann. tit. 63, §§ 1–738.2, −741.12 (2011). Arizona Senate passed a similar bill. Associated Press, “Senate Approves Bill on ‘Wrongful Births,”’ Arizona Capitol Times, March 6, 2012, available at <http://azcapitoltimes.com/news/2012/03/06/senate-approves-bill-on-wrongful-births> (last visited April 18, 2015).+(last+visited+April+18,+2015).>Google Scholar
H.B. 1305, § 2(1)(b), 63d Leg. Assemb. (N.D. 2013) (including “any physical disfigurement, scoliosis, dwarfism, Down syndrome, albinism, or any other type of physical or mental disability, abnormality, or disease”).Google Scholar
H.B. 386, 97th Gen. Assemb., 2013 Sess. (Mo. 2013). The bill included a list of conditions covered by the phrase “fetal diagnosis,” such as Down syndrome.Google Scholar
See, e.g., Utah Code Ann. § 76-7-302 (2010); Md. Code Ann., Health-Gen. § 20–209(b)(2)(ii) (1982); Tex. Health & Safety Code § 170.002(b)(3) (1998).Google Scholar
Ga. Code Ann. § 31–9B-2; Vernon's Texas Statutes and Codes Annotated § 171.046; West's Utah Code Annotated § 76-7-302; West's Louisiana Statutes Annotated § 1299.30.1.Google Scholar
2014 MS H.B. 1400.Google Scholar
Ariz. Rev. Stat. Ann. § 13–3603.02 (2011).Google Scholar
Okla. Stat. tit. 63, § 1–731.2.B (2012).Google Scholar
S.B. 353, Gen. Assemb., 2013 Sess. (N.C. 2013).Google Scholar
H.B. 2377, 84th Leg. Assemb., 2011 Reg. Sess. (Kan. 2011).Google Scholar
H.R. 1305, 63d Leg. Assemb., Reg. Sess. (N.D. 2013).Google Scholar
S.D. Codified Laws § 34–23A (2014).Google Scholar
18 Pa. Cons. Stat. Ann. § 3204(c) (1982) (“No abortion which is sought solely because of the sex of the unborn child shall be deemed a necessary abortion.”); 720 Ill. Comp. Stat. Ann. 510/6-(8) (1975); Ariz. Rev. Stat. Ann. § 13–3603.02 (2011) (note that Arizona is the only state to currently ban both sex and race-based abortions); Okla. Stat. tit. 63, § 1–731.2(B) (2011).Google Scholar
S.D. Codified Laws § 34–23A-10.1 (2014).Google Scholar
Id., § 34–23A-34 (2014).Google Scholar
PRENDA § 2(a)(1)(C).Google Scholar
Id.Google Scholar
PRENDA § 250(h)(2). The race provisions of PRENDA suggest troubling stereotypes and are difficult to understand. PRENDA devotes only two pages of the twenty-five page bill to race-based terminations. It is unclear how a provider would determine that abortion is “because the child or a parent of the child is of an undesired race” or “motivated by race bias.” Id., § 2(c). As many commentators have noted rightly, the overly simplistic and confused invocation of race and racial eugenics “promotes anti-immigrant sentiments, stigmatizes and discriminates against women of color by suggesting they cannot be trusted to make their own reproductive health care decisions.” The American Civil Liberties Union challenged, unsuccessfully, Arizona's law banning race-based abortions. See Mason Pieklo, J., “Advocates Ask Ninth Circuit to Reinstate Challenge to Arizona Race- and Sex-Selection Abortion Ban,” RH Reality Check, March 13, 2014, available at <http://rhrealitycheck.org/article/2014/03/13/advocates-ask-ninth-circuit-reinstate-challenge-arizona-race-sex-selection-abortion-ban/> (last visited April 18, 2015). (last visited April 18, 2015).' href=https://scholar.google.com/scholar?q=PRENDA+§+250(h)(2).+The+race+provisions+of+PRENDA+suggest+troubling+stereotypes+and+are+difficult+to+understand.+PRENDA+devotes+only+two+pages+of+the+twenty-five+page+bill+to+race-based+terminations.+It+is+unclear+how+a+provider+would+determine+that+abortion+is+“because+the+child+or+a+parent+of+the+child+is+of+an+undesired+race”+or+“motivated+by+race+bias.”+Id.,+§+2(c).+As+many+commentators+have+noted+rightly,+the+overly+simplistic+and+confused+invocation+of+race+and+racial+eugenics+“promotes+anti-immigrant+sentiments,+stigmatizes+and+discriminates+against+women+of+color+by+suggesting+they+cannot+be+trusted+to+make+their+own+reproductive+health+care+decisions.”+The+American+Civil+Liberties+Union+challenged,+unsuccessfully,+Arizona's+law+banning+race-based+abortions.+See+Mason+Pieklo,+J.,+“Advocates+Ask+Ninth+Circuit+to+Reinstate+Challenge+to+Arizona+Race-+and+Sex-Selection+Abortion+Ban,”+RH+Reality+Check,+March+13,+2014,+available+at++(last+visited+April+18,+2015).>Google Scholar
Id., § 250(b).Google Scholar
See, e.g., S.D. Cod. Laws § 34–23A-34 (2004).Google Scholar
Okla. Stat. Ann. tit 63, §§ 1–738i-738p (2010).Google Scholar
Fla. Stat. Ann. § 390.0112 (West 2013).Google Scholar
Ariz. Rev. Stat. Ann. § 13–3603.02 (2011).Google Scholar
Kohm, L. M., “Sex Selection Abortion and the Boomerang Effect of a Woman's Right to Choose: A Paradox of the Skeptics,” William and Mary Journal of Women & the Law 4, no. 1 (1997): 91–128, at 120.Google Scholar
National Society for Genetic Counselors, State Laws, available at <http://nsgc.org/p/cm/ld/fid=19> (states with licensing laws are California, Delaware, Illinois, Indiana, Massachusetts, Nebraska, New Mexico, Ohio, Oklahoma, Pennsylvania, South Dakota, Tennessee, Washington).+(states+with+licensing+laws+are+California,+Delaware,+Illinois,+Indiana,+Massachusetts,+Nebraska,+New+Mexico,+Ohio,+Oklahoma,+Pennsylvania,+South+Dakota,+Tennessee,+Washington).>Google Scholar
State Licensure for Genetic Counselors, Model Legislative Provisions, available at <http://nsgc.org/p/cm/ld/fid=18> (last visited April 18, 2015).+(last+visited+April+18,+2015).>Google Scholar
Neb. Stat. Rev. § 38-186-24 (2012).Google Scholar
Va. Code Ann. § 54.1–2957.20 (2014).Google Scholar
National Society of Genetic Counselors, Genetic Counselor Scope of Practice, available at <http://www.cap.org/apps/docs/statline/pdf/nsgc_genetic_counselor_scope_of_practice.pdf> (last visited April 18, 2015); Va. Code Ann. § 54.1–2900 (2014); Neb. Stat. Rev. § 38-186-15 (2012).+(last+visited+April+18,+2015);+Va.+Code+Ann.+§+54.1–2900+(2014);+Neb.+Stat.+Rev.+§+38-186-15+(2012).>Google Scholar
Mich. Comp. Law §§ 333.17020 (2)(a-f) (1978).Google Scholar
Minna Stern, A., Telling Genes: The Story of Genetic Counseling in America (Baltimore: Johns Hopkins University Press, 2012): At 166–167 (describing, with the introduction of amniocentesis, the debate among bioethicists about the permissible reasons for abortion and whether counselors should take a value-neutral view or try to dissuade individuals from termination for particular reasons, like sex).Google Scholar
Thomson-Deveaux, A., “Fetal Abnormalities: The Next Minefield in the Abortion Wars?” American Prospect, April 9, 2014, available at <http://prospect.org/article/fetal-abnormalities-next-minefield-abortion-wars> (last visited April 18, 2015).+(last+visited+April+18,+2015).>Google Scholar
Gold, R. B., “Lessons from Before Roe: Will Past Be Prologue?” Guttmacher Institute, March 2003, 1–11: At 10, available at <http://www.guttmacher.org/pubs/tgr/06/1/gr060108.pdf> (last visited April 18, 2015) (“In some states, especially between 1967 and 1973, a woman also could receive approval for an abortion if it were deemed necessary to protect her physical or mental health.”).Google Scholar
Dorr, G. M., “Protection or Control? Women's Health, Sterilization Abuse, and Reif v. Weinberger,” in Lombardo, P., ed., A Century of Eugenics: From the Indiana Experiment to the Human Genome Era (Bloomington: Indiana University Press, 2011): At 163 (describing the history of laws on involuntary sterilization and noting practices of involuntary sterilization); see also Daar, supra note 40, at 216 (by the 1930s, thirty states had involuntary sterilization laws).Google Scholar
See Mutcherson, , supra note 44, at 342–343.Google Scholar
See Stern, , supra note 104, at 174.Google Scholar
Id., at 15.Google Scholar
Id., at 9.Google Scholar
Id., at 95.Google Scholar
Bernhardt, B. A. et al., “Women's Experiences Receiving Abnormal Prenatal Chromosomal Microarray Testing Results,” Genetics in Medicine 15, no. 2 (2013): 139–145, at 140.Google Scholar
Id., at 140.Google Scholar
See Mutcherson, , supra note 44, at 324–325.Google Scholar
See Klitzman, , supra note 7, at 233.Google Scholar
See Bernhardt, et al., supra note 103, at 143.Google Scholar
Id.Google Scholar
See Farrell, , supra note 23, at 6.Google Scholar
Rothman, B., “The Tentative Pregnancy: Then and Now,” in Rothenberg, K. H. Thompson, E. J., eds., Women and Prenatal Testing: Facing the Challenges of Genetic Technology (Columbus: The Ohio State University Press, 1994): At 260; Rothenberg, K. H., “The Law's Response to Reproductive Genetic Testing: Questioning Assumptions about Choice, Causation, and Control,” Fetal Diagnosis & Therapy 8, no. 1 (1993): 160–163, at 160.Google Scholar
Prenatally & Postnatally Diagnosed Conditions Awareness Act, Pub. L. No. 110–374, § 3, 122. Stat. 4051, 4051–54 (2008) (amending the Public Health Service Act 42, U.S.C. § 254c-8(e) (2006)).Google Scholar
See de Jong, et al., supra note 24, at 274.Google Scholar
See Benn, Chapman, , supra note 55, at 131.Google Scholar
See Stern, , supra note 95, at 147 (describing the evolution of genetic counseling as more patients sought prenatal diagnosis).Google Scholar
Farrell, R. M., “Women and Prenatal Genetic Testing in the 21st Century,” Health Matrix 23, no. 1 (2013): 1–13, at 7–8.Google Scholar
See Melhman, M., “Modern Eugenics and the Law,” in Lombardo, P., ed., A Century of Eugenics: From the Indiana Experiment to the Human Genome Era (Bloomington: Indiana University Press, 2011): At 221 (describing modern incentives, which straddle private decision-making and state regulation, that “encourage or discourage the birth of specific types of individuals”).Google Scholar
Barber, P. L., “Prenatal Diagnosis: An Ethical and a Regulatory Dilemma,” Houston Journal of Health, Law and Policy 13, no. 2 (2013): 329–351; Deans, Z. Newson, A. J., “Should Non-Invasiveness Change Informed Consent Procedures for Prenatal Diagnosis?” Health Care Analysis 19, no. 2 (2011): 122–123, at 122; Schmitz, D. et al., “An Offer You Can’t Refuse? Ethical Implications of Non-Invasive Prenatal Diagnosis,” Nature Reviews Genetics 10, no. 8 (2009): 515–516, at 515.Google Scholar
See Stern, , supra note 95, at 174.Google Scholar
See de Jong, Maya, van Litht, , supra note 22, at 8.Google Scholar
American College of Obstetricians and Gynecologists Committee on Genetics, The Society for Maternal-Fetal Medicine, Committee Opinion No. 545, Noninvasive Prenatal Testing for Fetal Aneuploidy (December 2012).Google Scholar
See Benn, Chapman, , supra note 56, at 130.Google Scholar
See Suter, , supra note 17, at 233.Google Scholar
See de Jong, et al., supra note 24, at 273; Mutcherson, supra note 44, at 325.Google Scholar
Donley, G. et al., “Prenatal Whole Genome Sequencing: Just Because We Can, Should We?” Hastings Center Report 42, no. 4 (2012): 28–40, at 28–30.Google Scholar
Dickens, B., “Ethical and Legal Aspects of Noninvasive Prenatal Genetic Diagnosis,” International Law Journal of Gynecology & Obstetrics 124, no. 2 (2014): 181–185, at 182 (“safe access to fetal DNA might make fetuses amenable to techniques that test for a much broader range of genetic abnormalities such as susceptibility to breast cancer and late-onset disorders, and even extend to whole-genome or whole-exome sequencing”).Google Scholar
See de Jong, et al., supra note 24, at 275; Dickens, supra note 126, at 183.Google Scholar
Id., at 274.Google Scholar
Gregory Feero, W. et al., “Genomic Medicine—An Updated Primer,” New England Journal of Medicine 362, no. 21 (2010): 2001–2011; Burke, W. Brown Trinidad, S. Wright Clayton, E., “Seeking Genomic Knowledge: The Case for Clinical Restraint,” Hastings Law Journal 64, no. 6 (2013): 1650–1664, at 1649.Google Scholar
Garel, M. et al., “Ethical Decision-Making in Prenatal Diagnosis and Termination of Pregnancy: A Qualitative Survey among Physicians and Midwives,” Prenatal Diagnosis 22, no. 9 (2002): 811–817, at 812–813.Google Scholar
See Benn, Chapman, , supra note 56, at 130.Google Scholar
See de Jong, de Wert, , supra note 46, at 52.Google Scholar
Id., at 52.Google Scholar
Id., at 52–53.Google Scholar
See Dickens, , supra note 138, at 182.Google Scholar
The International Federation of Gynecology and Obstetrics (FIGO) Ethical Guidelines on Conscientious Objection require that, “Practitioners provide [their] patients with timely access to medical services, including giving information about the medically indicated options of procedures for their care and of any such procedures in which their practitioners object to participate on grounds of conscience.”Google Scholar
Chachkin, C. J., “What Potent Blood: Non-Invasive Prenatal Genetic Diagnosis and the Transformation of Modern Prenatal Care,” American Journal of Law & Medicine 33, no. 1 (2007): 9–53, at 23–24.CrossRefGoogle Scholar
See Stern, , supra note 95, at 10.Google Scholar
See Dickens, , supra note 125, at 183.Google Scholar
See Benn, Chapman, , supra note 56, at 132.Google Scholar
Ranji, U. Salginicoff, A., Focus on Health Reform: Access to Abortion Coverage and Health Reform (Washington, D.C.: The Henry J. Kaiser Family Foundation, 2010): At 1, 6.Google Scholar
Guttmacher Institute, State funding of Abortion under Medicaid, 2014.Google Scholar
Take for example the Priority Health coverage policy. The coverage policy requires counseling and informed consent before testing. See Priority Health, supra note 6, at 1.Google Scholar
In describing the routine coverage of private plans and public programs, the IOM report stated: “Pregnant women should receive…prenatal screening and testing for neural tube defects (for all women at elevated risk) and chromosomal abnormalities (for all women at “elevated risk”), including, but not limited to amniocentesis, chorionic villus sampling, and ultrasound.” Commission on Preventive Services for Women, Clinical Preventive Services For Women: Closing the Gaps (Washington, D.C.: Institute of Medicine, 2011): At 61.Google Scholar
See Priority Health, supra note 6, at 7.Google Scholar
See Stern, , supra note 95, at 122, 136.Google Scholar
See Farrell, , supra note 116, at 9–11 (problematizing the “voluntariness” of NIPT, based on women's experiences with amniocentesis and CVS).Google Scholar
See de Jong, Maya, van Litht, , supra note 22, at 8.Google Scholar